Latest News about JP:4523
Recent news which mentions JP:4523
Merck and Eisai say two lung-cancer trials failed to meet their main goals
September 22, 2023
From MarketWatch
Tags
JP:4523
From MarketWatch
New Alzheimer’s drug could bring hope to patients, but could be out of reach for people on Medicare
May 25, 2023
Tickers
BIIB
From MarketWatch
Eli Lilly’s positive results from a Alzheimer’s trial seen as ‘potentially very important’
May 03, 2023
From MarketWatch
Healthcare merger mania scrutinized on Capitol Hill as new deal combines major health systems
April 26, 2023
Tickers
BIIB
From MarketWatch
Tickers
BIIB
From MarketWatch
Wall Street predicts approval for another ALS drug
March 21, 2023
From MarketWatch
From MarketWatch
FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments
February 28, 2023
From MarketWatch
New Alzheimer’s drug shows some promise, but has big price tag
February 02, 2023
From MarketWatch
Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug
January 20, 2023
From MarketWatch
Amid criticism for its handling of another Alzheimer’s drug, FDA will decide this week whether to approve lecanemab
January 03, 2023
From MarketWatch
New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’
December 09, 2022
Tickers
BIIB
From MarketWatch
5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners
November 30, 2022
From MarketWatch
Banks are short more than $1 trillion in capital, this analyst says, who fears the shortfall will only get worse
November 30, 2022
From MarketWatch
A new Alzheimer’s treatment may help some patients, though researchers say more safety data is needed
November 29, 2022
Tickers
BIIB
From MarketWatch
Eisai shares fall following report of patient death in Alzheimer’s trial
November 28, 2022
Tickers
BIIB
From MarketWatch
What to know about the Alzheimer’s drug data coming out this week
November 28, 2022
From MarketWatch
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
November 14, 2022
From MarketWatch
From MarketWatch
Medicare coverage of Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
September 28, 2022
From MarketWatch
Here’s why one strategist says the consumer and related stocks might get a second wind
September 28, 2022
From MarketWatch
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
September 28, 2022
From MarketWatch
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
September 28, 2022
From MarketWatch
Alzheimer’s drug from Eisai, Biogen shows promise in large trial
September 27, 2022
Tickers
BIIB
From MarketWatch
Eisai shares sink after Japan regulators seek more data for review of Alzheimer’s drug
December 22, 2021
Tickers
BIIB
From MarketWatch